Microneedle Patch Drug Delivery 2026 — PatSnap Eureka
Microneedle Patch Drug Delivery: Patent & Innovation Intelligence
From dissolving polymer arrays to CAR-T cell scaffolds and closed-loop glucose management — the 2026 microneedle patch landscape spans 80+ patent and literature records across five structural archetypes, six therapeutic domains, and a decisive shift toward clinical translation. Explore the full IP map with PatSnap Eureka.
How Microneedle Patches Bypass the Skin Barrier
Microneedle patch technology centres on arrays of microscale projections — typically 100–900 µm in height — that penetrate the outer skin layers, primarily the stratum corneum (10–20 µm thick), to create transient microchannels for drug permeation or direct intradermal drug deposit. This minimally invasive approach delivers therapeutics ranging from small molecules to macromolecules, vaccines, nucleic acids, and even living cells, with precision, patient compliance, and reduced pain compared to conventional hypodermic injection.
Core materials documented in the dataset include biodegradable polymers (explored via PatSnap's chemical intelligence platform) such as PLGA, PLA, and PCL, alongside hydrophilic polymers (PVA, PVP, hyaluronic acid, CMC), natural biopolymers (silk fibroin, chitosan, dextran), and advanced composites incorporating nanoparticles, nanofibers, and lipid nanoparticles. Fabrication methods include micromolding, lithography, nanoimprint lithography, 3D printing, solvent casting, and layer-by-layer (LbL) coating.
The field has matured from early conceptual frameworks into active clinical translation, with accelerating innovation in stimuli-responsive systems, bioresponsive materials, and combination nano-micro architectures. According to WHO global immunisation strategy, needle-free delivery platforms are a priority for pandemic preparedness — a trend directly driving MN patch investment. Patent activity in this dataset spans from 1988 to 2026, with the clear majority of innovation filings clustered in 2017–2025.
Patent Landscape at a Glance
Key quantitative signals from the microneedle patch patent and literature dataset, analysed via PatSnap Eureka across 80+ records spanning 1988–2026.
Application Domain Distribution
Vaccine & immunotherapy is the most heavily documented application domain, followed by diabetes & metabolic disease management.
Key Assignee Patent Filing Activity
LEO Pharma A/S leads with 4 filings across multiple jurisdictions; University of California and COSMED each hold 2 active filings.
Innovation Phase Trajectory (1988–2026)
Filing activity clustered sharply in 2017–2025, with the most advanced biological payloads (mRNA, CAR-T) appearing only in 2024–2025.
Patent Filing by Jurisdiction
EP and US dominate active filings; WO (PCT) signals global commercialisation intent; CN-origin filings remain sparse despite heavy Chinese academic output.
Four Principal Innovation Clusters in Microneedle Drug Delivery
The patent and literature dataset organises into four distinct technology clusters, each with characteristic materials, mechanisms, and leading assignees. Explore the full cluster map via PatSnap Analytics.
Dissolving & Biodegradable Microneedles
The dominant paradigm in the dataset. Dissolving MNs are fabricated from water-soluble or biodegradable polymers (HA, PVA, PVP, CMC, PLGA, PLA) that encapsulate drug cargo and dissolve upon skin insertion, releasing payload without leaving sharps waste. Sub-variants include rapid-dissolving tips (seconds to minutes), slow-dissolving sustained-release formulations, and tip-separation designs enabling short application times critical for patient compliance in chronic disease management. The Gyeongsang National University patent (US, 2025) claims drug loadings up to 100 mg/cm² — an order-of-magnitude improvement over conventional MN patches.
LEO Pharma EP active · Gyeongsang US 2025 · Shilla EP 2023Stimuli-Responsive & Smart Microneedles
An emerging and rapidly growing cluster. These systems release drug cargo on-demand in response to internal physiological signals (glucose levels, reactive oxygen species, pH) or external triggers (light, ultrasound, mechanical actuation). The bioresponsive approach is especially prominent in diabetes management via glucose-responsive polymer matrices. North Carolina State University's core-shell glucose-responsive device (EP, 2021) uses PVA cross-linked with peroxide-sensitive linkers and glucose-responsive nanogels. The University of California's dual-responsive hybrid patch (EP, 2025) releases insulin under hyperglycemic and glucagon under hypoglycemic conditions — a closed-loop glucose management approach requiring no electronic components.
NC State EP 2021 · UC California EP 2025 · Veradermics IL 2022Nanoparticle-Integrated & Advanced Material MNs
This cluster covers the combination of nanoscale drug carriers — PLGA microparticles, lipid nanoparticles, layered double hydroxide (LDH) nanocomposites, dendrimer-coated hydrogels, bacterial cellulose nanofibers — within MN matrices to extend release duration, improve mechanical strength, and enable delivery of nucleic acids and large biologics. The City University of Hong Kong patent (US, 2024) introduces lipid nanoparticle-encapsulated nucleic acid drugs within room-temperature-stable dissolvable MN patches — directly addressing cold chain and injection barriers that constrained mRNA vaccine deployment. LbL coating strategies from MIT represent a key intellectual lineage in this cluster.
City Univ. HK US 2024 · Georgia Tech EP 2022 · Manganiello WO 2025Hollow & Active-Delivery Microneedles
Hollow MNs function as microscale conduits connecting an external drug reservoir to the intradermal space via "poke-and-flow" mechanisms. The touch-actuated and wearable self-powered variants represent integration with electronics and energy harvesting for active, on-demand dosing. Passport Technologies (AU, 2026) presents a matrix-based patch designed for use with a porator device — lightweight (<100 g/m²) with low water-holding capacity optimised for rapid drug permeation through micropores. COSMED Pharmaceutical's spring-loaded applicator device (EP, 2018) delivers consistent and reproducible MN insertion force into skin, signalling a commercialisation-oriented engineering focus. Learn more about PatSnap's life sciences intelligence.
Passport Technologies AU 2026 · COSMED EP 2018 · Industrial Cosmetic Lab SG 2020Therapeutic Applications Documented in the 2026 Dataset
Six major therapeutic application domains are documented across the patent and literature records, from well-established vaccine delivery to nascent CAR-T cell oncology applications.
| Application Domain | Key Technology / Payload | Leading Assignees / Institutions | Status | Notable Detail |
|---|---|---|---|---|
| Vaccine & Immunotherapy | CMC, HA, PLGA dissolving MNs; antigen + adjuvant co-delivery | Veradermics, MIT, Nara Medical University | Most documented | 5-minute application for transcutaneous vaccination documented |
| Diabetes & Metabolic Disease | Glucose-responsive PVA, dual insulin/glucagon responsive matrix | NC State University, Univ. of California, Sun Yat-Sen Univ. | Most cited drug | Closed-loop insulin delivery without electronic components (UC, EP 2025) |
| Dermatology & Cosmetics | Retinoid NPs, PLA/PCL coated, HA wound healing patches | Charité Berlin, Inha University, COSMED, Shenyang Pharma Univ. | Active | COSMED applicator device targets cosmetic and skin treatment indications |
| Cancer & Cell Therapy | Porous honeycomb MN scaffold for CAR-T cell seeding | University of California (EP, 2025) | Emerging | Post-surgical solid tumor resection site delivery — paradigm-expanding |
Need Freedom-to-Operate Analysis Across These Domains?
PatSnap Eureka maps claim scope, assignee activity, and white-space opportunities in real time.
Five Forward-Looking Innovation Signals
Based on the most recent filings (2023–2026) in this dataset, five clear directions define where microneedle patch technology is headed. These signals are directly traceable to specific patent filings analysed via PatSnap.
Nucleic Acid & mRNA Delivery via MN Patches
The City University of Hong Kong patent (US, 2024) introduces lipid nanoparticle-encapsulated nucleic acid drugs within room-temperature-stable dissolvable MN patches, directly addressing the cold chain and injection barriers that constrained mRNA vaccine deployment. This is an extremely high-value direction given post-COVID mRNA vaccine infrastructure investment. Only one patent in this dataset directly addresses lipid nanoparticle/nucleic acid MN — representing an early-mover IP opportunity.
Living Cell Delivery: CAR-T and Beyond
The University of California's porous honeycomb microneedle patch for CAR-T cell seeding (EP, 2025) converts MN patches from passive drug carriers into active cell-delivery scaffolds for post-surgical solid tumor treatment. Only one patent in this dataset addresses CAR-T delivery — filing activity in this sub-domain remains sparse relative to commercial potential, representing an early-mover IP opportunity for oncology-focused organisations. See the full PatSnap customer case studies for pharma R&D applications.
Closed-Loop Bioresponsive Systems for Metabolic Disease
The University of California's dual-responsive insulin/glucagon hybrid patch (EP, 2025) and North Carolina State's core-shell glucose-responsive device (EP, 2021) together define a clear trajectory toward autonomous closed-loop endocrine management without electronic components — a purely materials-science-driven artificial pancreas analog. This direction draws from materials science, polymer chemistry, and bioelectronics simultaneously, requiring cross-disciplinary IP strategy across all three patent classes.
IP Strategy Implications for R&D and Patent Teams
Freedom-to-operate risk is highest in sustained-release tip-layer architectures. LEO Pharma's active EP grant covering biodegradable polymer tip with fast-dissolving backing layer represents a foundational claim in the dissolvable MN space. R&D teams developing chronic-disease patches in EP jurisdiction must assess design-around strategies carefully.
Nucleic acid and cell delivery are the highest-value white spaces. Only one patent in this dataset directly addresses lipid nanoparticle/nucleic acid MN (City University of Hong Kong, 2024), and one addresses CAR-T delivery (University of California, 2025). Filing activity in these sub-domains remains sparse relative to their commercial potential, representing an early-mover IP opportunity.
Geographic diversification of filing is a competitive signal. The observed concentration of active EP grants among US universities and EU pharma (LEO Pharma), combined with sparse CN-origin patent filings in this dataset — despite heavy Chinese academic publication activity from Wuhan University, Sun Yat-Sen, Beijing University of Chemical Technology, and CAS — suggests that Chinese innovators are publishing significantly more than they are protecting internationally. This represents both a potential prior art risk and a licensing opportunity for Western players. According to EPO filing trends, this pattern is common in emerging biomedical technology classes.
IP teams should map freedom-to-operate across materials science, polymer chemistry, and bioelectronics patent classes simultaneously, as the most advanced responsive systems draw from all three disciplines. PatSnap Analytics provides cross-class landscape mapping for exactly this type of multi-disciplinary FTO challenge.
Microneedle Patch Drug Delivery — key questions answered
The field spans five principal structural archetypes: solid, coated, dissolving/dissolvable, hollow, and hydrogel-forming microneedles, each associated with distinct drug loading and release paradigms. Dissolving MNs are the dominant paradigm, fabricated from water-soluble or biodegradable polymers such as HA, PVA, PVP, CMC, PLGA, and PLA.
Vaccine and immunotherapy delivery is the most heavily documented application. Insulin delivery represents the single most cited drug application in the dataset, spanning dissolved MN rollers, dissolving gelatin/CMC patches, touch-actuated patches, and the most advanced dual-responsive insulin/glucagon hybrid patch from the University of California (EP, 2025).
LEO Pharma A/S (Denmark) is the most prolific patent assignee in this dataset, with at least 4 filings across SG, IL, and EP jurisdictions for sustained-release biodegradable tip architecture; EP grant active. The Regents of the University of California have two recent EP-active filings (2025) covering CAR-T cell delivery and hybrid insulin/glucagon responsive patches — the most advanced biological payloads in this dataset.
Based on the most recent filings (2023–2026), five clear forward-looking directions are identifiable: (1) Nucleic acid and mRNA delivery via MN patches; (2) Living cell delivery (CAR-T and beyond); (3) Closed-loop bioresponsive systems for metabolic disease; (4) Expanded drug loading and high-dose architectures up to 100 mg/cm²; and (5) Scalable manufacturing and commercialization infrastructure.
Freedom-to-operate risk is highest in sustained-release tip-layer architectures: LEO Pharma's active EP grant covering biodegradable polymer tip with fast-dissolving backing layer represents a foundational claim in the dissolvable MN space. R&D teams developing chronic-disease patches in EP jurisdiction must assess design-around strategies carefully.
Microneedle patch drug delivery technology represents a minimally invasive transdermal platform that bypasses the stratum corneum barrier to deliver therapeutics — from small molecules to macromolecules, vaccines, nucleic acids, and living cells — with precision, patient compliance, and reduced pain compared to conventional hypodermic injection.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About MN PatentsMap the Full Microneedle Patent Landscape — Live, in Minutes
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. From FTO analysis to white-space identification across dissolving MN, mRNA delivery, and CAR-T cell scaffolds — Eureka gives your IP and R&D team the intelligence edge.
References
- Microneedle patch for delivering an active ingredient to the skin — LEO PHARMA A/S, 2021, EP
- Core-shell microneedle devices and uses thereof — North Carolina State University, 2021, EP
- Microneedle patch for immunostimulatory drug delivery — VERADERMICS INCORPORATED, 2022, IL
- Microneedle patch and method of fabrication thereof — City University of Hong Kong, 2024, US
- Microneedle patch for in-situ seeding of cells — The Regents of the University of California, 2025, EP
- Therapeutic hybrid microneedle patch for the delivery of insulin and glucagon — The Regents of the University of California, 2025, EP
- Microneedle array patches (MAPS), systems, and methods — Manganiello, Matthew, 2025, WO
- Microneedle patch system for transdermal drug delivery — Industry-Academic Cooperation Foundation, Gyeongsang National University, 2025, US
- Method for manufacturing a transdermal drug delivery patch — SHILLA INDUSTRIAL CO., LTD., 2023, EP
- Microneedle patches and systems — Georgia Tech Research Corporation, 2022, EP
- Microneedle patch case — COSMED PHARMACEUTICAL CO., LTD., 2022, EP
- Microneedle patch application device and patch holder — COSMED PHARMACEUTICAL CO., LTD., 2018, EP
- Transdermal drug delivery patch, drug delivery system and drug delivery method — PASSPORT TECHNOLOGIES, INC., 2026, AU
- A microneedle patch for transdermal injections — Industrial Cosmetic Lab LLC, 2020, SG
- A microneedle patch and a method of preparation thereof — BITS Pilani, 2023, IN
- Microneedles in Drug Delivery: Progress and Challenges — Imperial Bioscience Ltd., 2021, Literature
- Application of microneedle patches for drug delivery; doorstep to novel therapies — Tabriz University of Medical Sciences, 2022, Literature
- Rapidly separable microneedle patches for controlled release of therapeutics for long-acting therapies — Wuhan University, 2022, Literature
- Stimuli-responsive transdermal microneedle patches — Istituto Italiano di Tecnologia, 2021, Literature
- The most promising microneedle device: present and future of hyaluronic acid microneedle patch — Shenyang Pharmaceutical University, 2022, Literature
- World Health Organization (WHO) — Global Immunisation Strategy & Needle-Free Delivery Platforms
- European Patent Office (EPO) — Patent Filing Trends in Biomedical Technology
- Massachusetts Institute of Technology (MIT) — Layer-by-Layer Coating and Composite Dissolving MN Research
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.